IL6R and metabolic dysfunction-associated steatotic liver disease: In another study, sIL-6R was lower in advanced compared to early NAFLD [194], which may imply a lower activation of trans-signaling when the disease advances, as a potentially counterbalancing mechanism against the disease progression; however, this remains to be shown.